BioMark Diagnostics (TSE:BUX) has released an update.
BioMark Diagnostics Inc. has made significant strides in breast cancer detection, unveiling groundbreaking research that enhances their liquid biopsy platform. Their innovative AI-driven metabolomics technology shows promise for early detection, especially of lobular breast cancer, potentially offering a cost-effective and reliable blood-based screening solution.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.